Healthcare provider profile · identity verified

Shailesh Baral, MD

Endocrinology · YORK, PA · NPI 1568628485

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	452	136
Ozempic	Semaglutide	359	80
Jardiance	Empagliflozin	354	97
Levothyroxine Sodium	Levothyroxine Sodium	323	94
Rybelsus	Semaglutide	265	71
Glipizide	Glipizide	258	67
Novolog Flexpen	Insulin Aspart	246	86
Metformin Hcl Er	Metformin Hcl	243	72
Alendronate Sodium	Alendronate Sodium	227	64
Trulicity	Dulaglutide	224	67
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	195	78
Metformin Hcl	Metformin Hcl	185	57
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	148	34
Glipizide Er	Glipizide	143	38
Mounjaro	Tirzepatide	139	29
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	116	42
Humalog Kwikpen U-100	Insulin Lispro	114	45
Atorvastatin Calcium	Atorvastatin Calcium	102	27
Farxiga	Dapagliflozin Propanediol	102	29
Tresiba Flextouch U-100	Insulin Degludec	96	26
Methimazole	Methimazole	89	28
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	89	37
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	79	30
Repaglinide	Repaglinide	70	22
Novolin N Flexpen	Insulin Nph Human Isophane	64	20
Januvia	Sitagliptin Phosphate	61	14
Prolia	Denosumab	60	37
Rosuvastatin Calcium	Rosuvastatin Calcium	57	13
Testosterone	Testosterone	56	11
Humulin R U-500 Kwikpen	Insulin Regular, Human	52	14
Hydrocortisone	Hydrocortisone	50	14
Pioglitazone Hcl	Pioglitazone Hcl	49	13
Soliqua 100-33	Insulin Glargine/Lixisenatide	37	suppressed
Amlodipine Besylate	Amlodipine Besylate	36	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	36	11
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	36	suppressed
Novolog	Insulin Aspart	35	12
Teriparatide	Teriparatide	35	suppressed
Lisinopril	Lisinopril	34	13
Cinacalcet Hcl	Cinacalcet Hcl	33	suppressed
Insulin Aspart Flexpen	Insulin Aspart	33	14
Tradjenta	Linagliptin	30	suppressed
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	29	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	29	14
Fiasp Flextouch	Insulin Aspart (Niacinamide)	27	12
Insulin Lispro Kwikpen U-100	Insulin Lispro	27	13
Synthroid	Levothyroxine Sodium	27	suppressed
Synjardy	Empagliflozin/Metformin Hcl	25	suppressed
Calcitriol	Calcitriol	24	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	24	suppressed
Risedronate Sodium	Risedronate Sodium	24	suppressed
Ultra-Fine Original Pen Needle	Pen Needle, Diabetic	24	suppressed
Ezetimibe	Ezetimibe	23	suppressed
Cabergoline	Cabergoline	20	suppressed
Gabapentin	Gabapentin	20	suppressed
Icosapent Ethyl	Icosapent Ethyl	20	suppressed
Levemir Flexpen	Insulin Detemir	20	13
Tresiba Flextouch U-200	Insulin Degludec	19	suppressed
Dapagliflozin	Dapagliflozin Propanediol	18	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	18	suppressed
Losartan Potassium	Losartan Potassium	17	suppressed
Testosterone Cypionate	Testosterone Cypionate	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	16	suppressed
Liothyronine Sodium	Liothyronine Sodium	15	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	15	suppressed
Omnipod 5 Dexg7g6 Pods (Gen 5)	Insulin Pump Cart,auto,bt,g6/7	15	suppressed
Bydureon Bcise	Exenatide Microspheres	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Gvoke Hypopen 2-Pack	Glucagon	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Admelog Solostar	Insulin Lispro	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Metoprolol Succinate	Metoprolol Succinate	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	11	suppressed
Xigduo Xr	Dapaglifloz Propaned/Metformin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error